Abelacimab Outperforms Standard Anticoagulant with Marked Bleeding Reduction

Abelacimab, a dual-acting factor XI/XIa inhibitor, demonstrated a significant reduction in bleeding in a head-to-head study comparing a factor XI inhibitor to a direct oral anticoagulant.